NeOnc Technologies Share Price Today

NeOnc CEO buys 70K shares at $4.21 average; CMO adds to stake

CEO Amir Heshmatpour bought 70,000 shares at $4.21 average, totaling 150,000 recent shares. FDA granted Type B meeting for early January 2027 to discuss NEO100 accelerated approval. Short interest rose to 921,000 shares as of Oct 30, up from 876,682 on Oct 15. Phase 2a PFS-6 rate of 48.9% exceeded 20% benchmark, supporting Phase 3 trial design.

NeOnc to present brain cancer data at SNO meeting

NeOnc presents NEO100 and NEO212 data at SNO meeting on Nov 13, 2026. NEO100 targets IDH-mutant astrocytoma via intranasal delivery. NEO212 addresses TMZ-resistant glioblastoma with oral formulation. Analysts project $667 million operating income by 2033. Company plans pivotal trials for 500 patients across three countries.

NeOnc signs MoU with Abu Dhabi health dept for CNS research

NeOnc signed a non-binding MoU with Abu Dhabi DoH for CNS oncology research and clinical capability development. Two children in Abu Dhabi currently receive investigational NEO100; a third is expected to join this week. DoH granted IND authorization for NEO100 and NEO212 in June 2026 for adult and pediatric studies. Global brain cancer therapeutics market projected to reach $5.1 billion by 2030 and $6.99 billion by 2032.

NeOnc reports NEO100 clinical improvement in pediatric brain tumor case

NeOnc reports independent breathing and leg movement in a pediatric patient treated with NEO100. FDA End-of-Phase 1 meeting for NEO212 scheduled for November 17, 2026. Executives purchased approximately $629,000 in stock following positive Phase 2a results. NEO212 recommended Phase 2 dose set at 610 mg after toxicity observed at 810 mg.

NeOnc appoints FAB executive to board amid Abu Dhabi drug push

Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, joined NeOnc's board on October 9, 2026. NeOnc priced a $15 million registered direct offering following positive NEO100 Phase 2a results. NEO100 Phase 2a study showed 48.9% six-month progression-free survival against a 20% benchmark. CEO Amir F. Heshmatpour will speak at the Abu Dhabi Future Health Summit October 20–22, 2026. Series A convertible preferred stock was redeemed on September 17, eliminating potential dilution.

NeOnc secures UAE IND for NEO212; FDA meeting set for November

NeOnc Technologies Holdings secured UAE IND authorization for NEO212, creating an international clinical-development pathway alongside US FDA discussions. The FDA In-Person End-of-Phase 1 Type B Meeting for NEO212 is scheduled for November 17, 2026, to discuss trial design and accelerated approval pathways. Executives, including CEO Amir Heshmatpour, purchased approximately $629,000 in open-market shares following positive NEO100 Phase 2a results. NEO100 Phase 2a data showed 48.9% six-month progression-free survival against a 20% benchmark, with median overall survival of 26.09 months.